معرفی
Andrew Gibson serves as an Associate Professor at the Personalised Medicine Centre within the Health Futures Institute at Murdoch University, Western Australia, following prior affiliation with Murdoch's Centre for Molecular Medicine and Innovative Therapeutics.
His academic credentials include:
- Doctor of Philosophy in Immunology from the University of Liverpool (2012-2016), thesis: 'Utilisation of an in vitro T cell priming assay to characterise the effects of co-inhibitory signalling on the activation of antigen-specific T cells'
- Master of Research (MRes) in Translation Medicine from the University of Liverpool (2011-2012), specializing in immune phenotyping and T-cell priming models
- Bachelor of Science in Human Biology (Pharmacology) from the University of Liverpool (2008-2011), graduated with 1st Class Honors
His research integrates immunogenomics, drug hypersensitivity mechanisms, and T-cell immunology through advanced single-cell sequencing and in vitro cell culture platforms. He investigates how immunological parameters disrupt tolerance mechanisms to drive adverse drug reactions, with emphasis on identifying immunogenic risks of pharmaceuticals, chemicals, and biologics. As laboratory lead for drug hypersensitivity research, he develops predictive models for drug safety assessment.
Gibson actively collaborates on industrial research projects and clinical partnerships to evaluate immunogenic risk profiles, bridging academic research with pharmaceutical industry applications and clinical practice.
He directs the drug hypersensitivity research laboratory at Murdoch University, overseeing experimental platforms that combine immunopharmacology with genomic technologies to characterize drug-induced immune responses.
